Teva UK Latest News Feed

Teva UK Limited launches Latanoprost Eye Drops

2012-01-18 09:24:10

We are pleased to announce the day-one launch of Latanoprost 0.005% w/v Eye Drops solution 2.5ml.

It is indicated in the treatment of elevated intraocular pressure in patients with open angle glaucoma and ocular hypertension.

Latanoprost is currently available as Xalatan® (Latanoprost) from Pfizer Limited. Latanoprost is now available from Teva to fulfil generic prescriptions.

Latanoprost is available immediately in the
award-winning Teva 360 livery. The strength and presentation is as follows:

Product Latanoprost Eye Drops

Strength 0.005% w/v

Pack Size 2.5ml x 1

Indication Reduction of elevated intraocular pressure in patients with open angle glaucoma and ocular hypertension

Teva retail price £3.74

Brand price £12.48

Kim Innes, Commercial Director at Teva said: “As the leading generics company in the country and with the widest portfolio of our competitors, Teva continues to lead with strong product launches and patent expired products. This is our inaugural product launch for 2012 and our first day-one patent expiry of the year.

“It’s good for Pharmacy, because patent expiries provide them with the opportunities for increasing margins and keeping costs down. But, even more importantly, we’re providing high-quality medicines for patients whilst doing our bit to save the NHS over £9bn a year."

New or existing customers can order through their wholesaler or contact their local Teva Territory Sales Manager, or call 0800 085 8621.

To find out more about Teva UK Limited, visit www.tevauk.com.

*Brand price at 17 January 2012

-ENDS-

For media enquiries, contact the Teva UK Limited Media team on 01977 628500, or email media.enquiries@tevauk.com.

Notes to Editors:

About Teva UK Limited
Teva UK Limited is one of the UK’s top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd.

About Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,300 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 45,000 people around the world and reached $16.1 billion in net sales in 2010.

Stock shortage – Syntaris® (flunisolide)

2012-01-09 11:08:53

• Syntaris bottle Nasal Spray, Teva livery
Product Licence No 00530/0705, Product Code 231-10-FP1122, PIP code 035-6659

Syntaris is a branded product from Teva UK Limited, used in the treatment of rhinitis.

We are currently experiencing an interruption to our supply, from our supplier. As a result, we anticipate we will shortly be out of stock. We expect to be back in stock from summer 2012.

Healthcare professionals should be aware of this situation. In the event that patients are not able to access stocks of Syntaris, they are advised to consult with their healthcare professional to enable them to access alternative medication appropriate to them.

For medical information enquiries, please contact Teva UK Limited on 0207 540 7117 or e-mail medinfo@tevauk.com

For Syntaris stock enquiries, please contact the Teva UK Limited Customer Liaison team on 0800 590502.

Please help us serve the healthcare and patient community by including a reference to the above stock shortage in the next issue of your magazine and on your website.

-ENDS-

Date of preparation: January 2012. Ref: CPE/11/051

Notes to Editors:
For enquiries, please contact: Julie Booth, Communications Manager. Tel: 01977 628640 / 07785 341328, Email: julie.booth@tevauk.com

About Teva UK Limited
Teva UK Limited is one of the UK’s top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd.

About Teva
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,300 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 45,000 people around the world and reached $16.1 billion in net sales in 2010.

Teva UK Limited launches generic anti-obesity drug Orlistat

2011-12-12 14:09:31

We are delighted to announce the first generic launch of Orlistat, generic equivalent to Xenical® (Orlistat) from Roche.

Product Orlistat

Strength 120mg capsule

Pack size x 84

Teva Retail price £27.68

Orlistat from Teva UK Limited is available immediately as:
Product Strength Pack size Teva retail Price
Orlistat 120mg capsule x 84 £27.68

Savings
Kim Innes, Commercial Director at Teva said: “We’re delighted to be the first company to launch generic Orlistat in the UK.

“As the UK’s leading supplier of generics, we’re pleased not only to have the widest portfolio of our competitors, but also to show that we’re well-placed when it comes to innovation and being the first to market.”

Indication
Orlistat is a generic version of prescription-only Xenical® from Roche and is indicated in conjunction with a mildly hypocaloric diet for the treatments of obese patients with a body mass index (BMI) greater or equal to 30kg/m2, or overweight patients (BMI ≥ 28kg/m2) with associated risk factors.

New or existing customers can order through their local Teva Territory Sales Manager, by completing a online form found on www.tevauk.com, or by calling our dedicated Sales Liaison team on 0800 085 8621.

To find out more about Teva UK Limited, visit www.tevauk.com.

Teva UK Limited launches generic Valsartan and Valsartan HCTZ

2011-11-14 14:23:37

Teva UK Limited launches generic Valsartan and Valsartan HCTZ

We are pleased to announce the day-one launch of generic Valsartan tablets and capsules, and Valsartan Hydrochlorothiazide (HCTZ) tablets.

Valsartan is a generic version of Diovan® (Valsartan) and Valsartan HCTZ is the generic version Co-Diovan® (Valsartan HCTZ); both from Novartis. They are indicated in the treatments of Heart failure, Hypertension and Recent myocardial infarction.

Valsartan and Valsartan HCTZ are available immediately in the award-winning Teva 360 livery. The strengths and presentations are as follows:

40mg caps x 28    - £7.68
80mg caps x 28    - £7.68
160mg caps x 28 - £10.13
40mg tabs x 7        - £1.22
320mg tabs x 28   - £7.08
HCTZ 80/12.5mg tabs x 28 - £4.89
HCTZ 160/12.5mg tabs x 28 - £6.44
HCTZ 160/25mg tabs x 28 - £6.44

Kim Innes, Commercial Director at Teva said: “As the leading generics company in the country and with the widest portfolio of our competitors, Teva continues with strong product launches and patent expiries. We’ve already launched 19 products this year including now eight day one patent expiries, in a variety of strengths and pack sizes.

“It’s good for Pharmacy, because patent expiries provide them with the opportunities for increasing margins and keeping costs down. But, importantly, it also means that we continue to do our bit in saving the NHS over £7bn a year.”

New or existing customers can order through their local Teva Territory Sales Manager, by completing the online form, or calling on 0800 085 8621

To find out more about Teva UK Limited, visit www.tevauk.com.

-ENDS-

Richard Daniell appointed as Managing Director of Teva UK Limited

2011-11-01 16:17:19

Teva UK Limited has announced that Richard Daniell has been appointed as Managing Director, responsible for all Teva’s commercial activities in the UK.

Richard, 44, has a wealth of experience in the pharmaceutical industry; having amassed more than two decades of knowledge in Teva group companies. He has held the role of Commercial Operations Officer since 2009.

Dipankar Bhattacharjee, previous head of Teva in the UK, has been promoted within Teva to a wider European role where the UK will be one of the territories under his guidance.

“I’m excited about driving the future and vision of Teva in the UK”, said Richard. “We want to keep growing, and keep serving our customers well, and I’m confident we can do both of those things with the talented people we have in our team. I’m delighted to be leading such a forward-thinking organisation and I’m proud to be at the helm of one of the UK’s leading pharmaceutical companies.”

Richard is from New Zealand originally and moved to the UK in 1990. Outside of work he is a keen runner, and is a fan of English football and New Zealand rugby.

To find out more about Teva UK Limited, visit www.tevauk.com.

Teva UK Limited launches Olanzapine range

2011-10-07 10:20:01

We are pleased to announce the off-patent launch of generic Olanzapine Teva Film-Coated Tablets and Olanzapine Teva Orodispersible Tablets. These will be launched in Teva 360 livery.

Olanzapine is a generic version of ZyprexaTM (Olanzapine) from Eli Lilly and Company Limited and is indicated for the treatment of schizophrenia. Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response1.

It is also indicated for the treatment of moderate to severe manic episode. In patients whose manic episode has responded to Olanzapine treatment, Olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.

Olanzapine Teva Film-Coated Tablets from Teva UK Limited are available immediately in six strengths as 2.5mg, 5mg, 10mg, 15mg and 20mg in packs of 28 & 7.5mg in packs of 56.

Olanzapine Teva Orodispersible Tablets from Teva UK Limited are available immediately in four strengths as 5mg, 10mg, 15mg & 20mg in packs of 28.

The Teva retail prices for the product are:

2.5mg Film-Coated Tablets x 28 £5.46
5mg Film-Coated Tablets x 28 £10.93
7.5mg Film-Coated Tablets x 56 £32.78
10mg Film-Coated Tablets x 28 £21.85
15mg Film-Coated Tablets x 28 £29.80
20mg Film-Coated Tablets x 28 £39.73

5mg Orodispersible Tablets x 28 £12.02
10mg Orodispersible Tablets x 28 £21.85
15mg Orodispersible Tablets x 28 £32.78
20mg Orodispersible Tablets x 28 £43.70
Kim Innes, Commercial Director at Teva UK Limited said “We are delighted to be bringing a generic version of this product to the UK market, and at the same time further broaden our portfolio, which is the widest of any UK generics supplier.”

For more information contact Teva UK Limited on 01977 628500, or email general.enquiries@tevauk.com.

To find out more about Teva UK Limited, visit www.tevauk.com.

Teva pledges continued “Pharmacy Support”

2011-09-15 16:40:53

Teva UK Limited, the UK’s leading generics supplier, has pledged to continue to support pharmacy through its “Pharmacy Support” programme.

Pharmacy Support aims to provide pharmacists with tools and information to help them make the most of the challenges of the ever-evolving pharmacy landscape.

The first initiative to come under the Pharmacy Support umbrella is MUR Advantage® – a kit designed to help pharmacists unlock the potential income stream available through conducting Medicines Use Reviews. It is available to pharmacists in England and Wales and has been developed with careful consideration for the needs of a busy pharmacist. It contains items to help them conduct successful MURs – from information to help generate patient demand for the MUR service, and advice on how to approach a consultation, to items to assist in conducting an efficient and effective MUR consultation.

Kim Innes, Teva’s Commercial Director, commented: “We introduced the Pharmacy Support initiative as part of our aim to help provide pharmacy with the support it needs to fully embrace the pharmacy contract and maximise their revenue streams. We wanted to create something that would give our pharmacy customers real hands-on help in this ever-changing healthcare environment.”

Almost 500 of Teva’s pharmacy customers have received an MUR Advantage® pack since its launch in November 2010. The company hopes that the kit will become an important tool for pharmacists working in England and Wales, and says that more initiatives will be unveiled under the Pharmacy Support programme in the future.

MUR Advantage® is available free of charge to qualifying members of the Teva generics buying schemes (TevaOne and TevaTwo1). MUR Advantage® is available at a cost of £50 to non-qualifying pharmacists.

To find out more about MUR Advantage® visit http://tevascheme.tevauk.com/pharmacy/pharmacy-support. Alternatively, call the helpline free on 0800 085 8621, or speak to your local Teva Territory Sales Manager.

-ENDS-

Teva UK Limited launches generic Letrozole tablets

2011-07-27 15:32:16

We are pleased to announce the launch of generic letrozole film-coated tablets.

Letrozole is a generic version of Femara® (letrozole) from Novartis Pharmaceuticals UK Ltd and is indicated in the following therapeutic indications:

• Adjuvant treatment of post-menopausal women with hormone receptor-positive early breast cancer

• Extended adjuvant treatment of hormone-dependent early breast cancer in post-menopausal women who have received prior standard adjuvant tamoxifen therapy for 5 years

• First-line treatment in post-menopausal women with hormone-dependent advanced breast cancer

• Advanced breast cancer in women with natural or artificially-induced post-menopausal status after relapse or disease progression, who have previously been treated with anti-oestrogens.

Letrozole from Teva UK Limited is available immediately as 2.5 mg film-coated tablets in packs of 14 and 28, in the award-winning Teva 360 packaging, which has been designed to aid patient safety.

The Teva retail price for the product is £7.49 for the packs of 14 film-coated tablets and £12.73 for the packs of 28.

Kim Innes, Commercial Director at Teva UK Limited said “We are delighted to be bringing a generic version of this product to the UK market, and at the same time further broaden our portfolio, which is the widest of any UK generics supplier.”

To find out more about Teva UK Limited, visit www.tevauk.com.

-ENDS-

July 2011; GEN/11/037

For media enquiries, contact the Teva UK Limited Communications team on 01977 628500, or email media.enquiries@tevauk.com.

Notes to Editors:

About Teva UK Limited
Teva UK Limited is one of the UK’s top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd.

About Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,450 molecules and a direct presence in 60 countries. Teva's branded businesses focus on neurological, respiratory and women's health therapeutic areas as well as biologics. Teva's leading innovative product, Copaxone®, is the number one prescribed treatment for multiple sclerosis. Teva employs approximately 40,000 people around the world and reached $16.1 billion in net sales in 2010.

Teva calls for fair market access as atorvastatin trial date announced

2011-07-25 13:28:35

Following a court hearing on Friday, Teva UK Limited is pleased to announce that the trial in its atorvastatin patent invalidity case will be heard in November 2011.

The trial will take place at the High Court of Justice in London. A decision is expected a few weeks later. If Teva wins, all of its generic atorvastatin stock currently being held at wholesalers would be released for sale, ending Lipitor®’s (atorvastatin) exclusivity in the UK.

A Teva spokesperson said: “We are delighted to have sought – and achieved – this early trial date, some six months before the current UK patent expiry date for Lipitor®. Our view is that Pfizer’s patent protection for Lipitor® is invalid. We look forward to presenting our arguments for the invalidity of the patent in court and winning the case.”

The EU Commission’s 2009 Pharmaceutical Sector Inquiry [1] found that: “In 55% of patent litigation cases between originator and generic companies that involved a question of the disputed patent’s validity … the patents were annulled.” [2]

The spokesperson added: “We strongly support valid intellectual property. It promotes innovation, and eventually at patent expiry it creates a market for a generic drug. But we agree with the Inquiry, which highlighted areas where originator companies employ illegitimate ‘patent strategies’ to create barriers to fair generic competition.” [3,4]

Concluded the spokesperson: “Teva winning this trial will mean we can resume supply to our loyal customers as soon as possible. We intend to win.”

Ref: GEN/11/036
25 July 2011

- ENDS -

For media enquiries, contact the Teva UK Limited Communications team on 01977 628500, or email media.enquiries@tevauk.com.

References:
1. EU Commission Pharmaceutical Sector Inquiry Final Report. 8 July 2009.

2. EU Commission Pharmaceutical Sector Inquiry Final Report. 8 July 2009 point 501 states that:
As later shown the final outcome in 60% of opposition and appeal procedures against originator company's patents examined in this report was a revocation of the disputed patent. In addition to this, the scope of the patents was reduced in another 15%.
These procedures almost exclusively concerned secondary patents. Furthermore in 55 % of the patent litigation cases between originator and generic companies that involved a question of the disputed patent's validity and that reached a final judgement, the patents were annulled (43 of 78 cases).

3. The EU Commission Pharmaceutical Sector Inquiry Final Report. 8 July 2009, points 467-536. Of particular interest are points 469 and 528:
Point 469: In fact, patent strategies can form part of a company's tool-box348 which are used in order to protect continuous revenue streams from pharmaceutical products by preventing or delaying generic entry.
Point 528: As shown above, patent strategies can lead to significant uncertainty concerning the possibility of a legitimate and commercially viable generic entry. Patent clusters and/or divisionals may without further enforcement action by originator companies, thus delay generic entry until the patent situation is clearer or even discourage more risk-sensitive generic companies from entering altogether.

4. The EU Commission Pharmaceutical Sector Inquiry Final Report. 8 July 2009, point 1557 states that:
The report finds that originator companies use a variety of instruments to extend the commercial life of their medicines. The results of the sector inquiry suggest that the behaviour of companies contributes to the generic delay.

About Teva UK Limited
Teva UK Limited is one of the UK’s top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd.

About Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,450 molecules and a direct presence in 60 countries. Teva's branded businesses focus on neurological, respiratory and women's health therapeutic areas as well as biologics. Teva's leading innovative product, Copaxone®, is the number one prescribed treatment for multiple sclerosis. Teva employs approximately 40,000 people around the world and reached $16.1 billion in net sales in 2010.

Teva UK launches generic Amisulpride oral solution

2011-07-18 11:27:10

We are pleased to announce the launch of generic Amisulpride oral solution.

Amisulpride is a generic version of Solian® (amisulpride) Liquid from Sanofi-Aventis and is indicated for the treatment of acute and chronic schizophrenic disorders.

It is available immediately as 100mg/ml in 60ml bottles in Focus livery.

The Teva retail price for the product is £29.54.

Kim Innes, Commercial Director at Teva UK Limited said “We are delighted to be bringing a generic version of this product to the UK market, and at the same time further broaden our portfolio, which is the widest of any UK generics supplier.”

To find out more about Teva UK Limited, visit www.tevauk.com.

-ENDS-
Ref: CPE/11/022
July 2011

For media enquiries, contact the Teva UK Limited Communications team on 01977 628500, or email media.enquiries@tevauk.com.

Notes to Editors:

About Teva UK Limited
Teva UK Limited is one of the UK’s top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd.

About Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,450 molecules and a direct presence in 60 countries. Teva's branded businesses focus on neurological, respiratory and women's health therapeutic areas as well as biologics. Teva's leading innovative product, Copaxone®, is the number one prescribed treatment for multiple sclerosis. Teva employs approximately 40,000 people around the world and reached $16.1 billion in net sales in 2010.

Teva UK launches generic Exemestane film-coated tablets

2011-07-18 11:25:28

We are pleased to announce the launch of a generic version of exemestane film-coated tablets.

Exemestane is a generic version of Aromasin® (exemestane) from Pharmacia Ltd and is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breast cancer, following two to three years of initial adjuvant tamoxifen therapy. It is also indicated in the treatment of advanced breast cancer in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy.

Exemestane from Teva is available immediately in the award-winning Teva 360 livery, which is designed to aid patient safety, as 25mg film-coated tablets in packs of 30 and 90.

The Teva retail price for the product is £26.64 for the packs of 30, and for £79.92 the packs of 90 film-coated tablets.

Kim Innes, Commercial Director at Teva UK Limited, said: “We are pleased to be adding this product to our ever-expanding portfolio, which is the widest of any UK generics supplier.”

To find out more about Teva UK Limited, visit www.tevauk.com.

-ENDS-

Ref: GEN/11/030
July 2011

For media enquiries, contact the Teva UK Limited Communications team on 01977 628500, or email media.enquiries@tevauk.com.

Notes to Editors:

About Teva UK Limited
Teva UK Limited is one of the UK’s top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd.

About Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,450 molecules and a direct presence in 60 countries. Teva's branded businesses focus on neurological, respiratory and women's health therapeutic areas as well as biologics. Teva's leading innovative product, Copaxone®, is the number one prescribed treatment for multiple sclerosis. Teva employs approximately 40,000 people around the world and reached $16.1 billion in net sales in 2010.

Teva UK launches Spiroco XL (ropinirole) prolonged-release tablets

2011-07-18 11:22:56

We are pleased to announce the launch of Spiroco XL (ropinirole) prolonged-release tablets.

Spiroco XL is a generic version of Requip XL® (ropinirole) from GlaxoSmithKline and is indicated in the treatment of Parkinson’s disease.

Spiroco XL from Teva is available immediately in the award-winning Teva 360 livery, which is designed to aid patient safety, as 2mg, 4mg and 8mg prolonged-release tablets in packs of 28.

The Teva retail prices for the product are as follows:

Product Strength Pack Size Teva retail price
Spiroco XL 2mg tablets 28 £10.97
Spiroco XL 4mg tablets 28 £21.95
Spiroco XL 8mg tablets 28 £36.84

Kim Innes, Commercial Director at Teva UK Limited said “We are delighted to be bringing a generic version of this product to the UK market, and at the same time further broaden our portfolio, which is the widest of any UK generics supplier.”

To find out more about Teva UK Limited, visit www.tevauk.com.

-ENDS-

Ref: GEN/11/029
July 2011

For media enquiries, contact the Teva UK Limited Communications team on 01977 628500, or email media.enquiries@tevauk.com.

Notes to Editors:

About Teva UK Limited
Teva UK Limited is one of the UK’s top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd.

About Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,450 molecules and a direct presence in 60 countries. Teva's branded businesses focus on neurological, respiratory and women's health therapeutic areas as well as biologics. Teva's leading innovative product, Copaxone®, is the number one prescribed treatment for multiple sclerosis. Teva employs approximately 40,000 people around the world and reached $16.1 billion in net sales in 2010.

Teva UK launches generic Repaglinide tablets

2011-07-18 11:20:46

We are pleased to announce the launch of generic Repaglinide tablets.

Repaglinide is a generic version of Prandin® (repaglinide) from Daiichi Sankyo UK Ltd – a diabetes treatment.

It is available immediately in the award-winning Teva 360 livery, which is designed to aid patient safety, as 0.5mg, 1mg and 2mg tablets, in a range of pack sizes.

The Teva retail prices for the product are as follows:

Product Strength Pack Size Teva retail price
Repaglinide 0.5mg tablets 30 £0.98
Repaglinide 0.5mg tablets 90 £2.94
Repaglinide 1mg tablets 30 £0.98
Repaglinide 1mg tablets 90 £2.94
Repaglinide 2mg tablets 90 £2.94

Kim Innes, Commercial Director at Teva UK Limited said “We are delighted to be bringing a generic version of this product to the UK market, and at the same time further broaden our portfolio, which is the widest of any UK generics supplier.”

To find out more about Teva UK Limited, visit www.tevauk.com.

-ENDS-
Ref: GEN/11/027
June 2011

For media enquiries, contact the Teva UK Limited Communications team on 01977 628500, or email media.enquiries@tevauk.com.

Notes to Editors:

About Teva UK Limited
Teva UK Limited is one of the UK’s top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd.

About Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,450 molecules and a direct presence in 60 countries. Teva's branded businesses focus on neurological, respiratory and women's health therapeutic areas as well as biologics. Teva's leading innovative product, Copaxone®, is the number one prescribed treatment for multiple sclerosis. Teva employs approximately 40,000 people around the world and reached $16.1 billion in net sales in 2010.

Teva UK launches generic Levofloxacin tablets

2011-07-18 11:18:13

We are pleased to announce the launch of a generic version of levofloxacin tablets in a range of strengths and pack sizes.

Levofloxacin is a generic version of Tavanic® (levofloxacin) from Sanofi. In adults with infections of mild or moderate severity, levofloxacin tablets are indicated for the treatment of the following infections when due to levofloxacin-susceptible microorganisms: acute sinusitis, acute exacerbation of chronic bronchitis, community-acquired pneumonia, uncomplicated and complicated urinary tract infections, chronic bacterial prostatitis and skin and soft tissue infections.

Levofloxacin from Teva is available immediately in the award-winning Teva 360 livery, which is designed to aid patient safety, as 250mg tablets in packs of 5 and 10, and 500mg tablets in packs of 5 and 10.

The Teva retail prices for the product are as follows:
Product Strength Pack Size Teva retail price
Levofloxacin 250mg tablets 5 £1.08
Levofloxacin 250mg tablets 10 £2.17
Levofloxacin 500mg tablets 5 £1.94
Levofloxacin 500mg tablets 10 £2.17

Kim Innes, Commercial Director at Teva UK Limited said “We are delighted to be bringing a generic version of this product to the UK market, and at the same time further broaden our portfolio, which is the widest of any UK generics supplier.”

To find out more about Teva UK Limited, visit www.tevauk.com.

-ENDS-

Ref: GEN/11/026
June 2011

For media enquiries, contact the Teva UK Limited Communications team on 01977 628500, or email media.enquiries@tevauk.com.

Notes to Editors:

About Teva UK Limited
Teva UK Limited is one of the UK’s top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd.

About Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,450 molecules and a direct presence in 60 countries. Teva's branded businesses focus on neurological, respiratory and women's health therapeutic areas as well as biologics. Teva's leading innovative product, Copaxone®, is the number one prescribed treatment for multiple sclerosis. Teva employs approximately 40,000 people around the world and reached $16.1 billion in net sales in 2010.

Customer message: Further update on generic atorvastatin

2011-07-12 09:46:10

11 July 2011

Dear customer

Further update on generic atorvastatin

We’d like to thank you for the trust and loyalty that you’ve placed in us with generic atorvastatin.

You’ll be aware that we launched this product on 20th June, and you’ll also be aware that Pfizer was granted a temporary injunction on that date against us, AAH and Phoenix that prevented those three parties accepting any more orders at least until a full hearing scheduled for 11th July.

As the dispute around the interim injunction has been resolved following an agreement between the parties, the case will now go straight to trial where the validity of the Pfizer’s patent will be debated. As a result, we can confirm there is no change around the current status with the supply and dispensing of generic atorvastatin:

• Pharmacies are not prevented from dispensing generic atorvastatin they have already purchased.
• No retail pharmacy is the subject to an injunction.
• In the unlikely event that Pfizer takes any action against dispensing pharmacists, Teva stands by its promise to provide full legal assistance and support.
• Teva and the wholesalers cannot ship any further generic atorvastatin orders.

Our view remains that Pfizer’s patent protection in place for Lipitor® (atorvastatin) is invalid. We believe the validity of Pfizer’s patent is an issue that is appropriately determined in the courts between Teva and Pfizer and does not need to involve pharmacy.

We are disappointed with Pfizer’s continuing attempts to frighten individual pharmacies by threatening to drag you into the patent litigation case. The choice whether to dispense generic atorvastatin is yours and yours alone to make. But, one question you must ask yourself is why Pfizer is attempting to act in this way and whether succumbing to this sort of bullying tactic is in the best interests of pharmacy in the long-term. We’d like to underline what Mr Justice Floyd said on 27 June, which was that ‘the actual dispensing of the product is not the basis of the harm to the claimants.’

We stand by you, and reiterate the promise that we are willing to provide all legal costs and pay all damages for any pharmacy who is sued by Pfizer. We feel strongly that we are acting in the interests of sustainable healthcare delivered via the pharmacy.

We look forward to the trial, which we intend to win and then resume supply to you – our loyal customers – as soon as possible. We will keep you informed when we have further news.

If you have any questions, please call Teva’s direct helpline on 0800 085 8621.

We want to be your preferred generics manufacturer today and tomorrow, and we believe strongly that we always try to act in your best interests.

Yours faithfully

Teva UK Limited

GEN/11/032a. Date of preparation: July 2011

Teva thanks pharmacy and reaffirms support as atorvastatin case continues

2011-07-12 09:41:22

Teva UK Limited has repeated its offer made last week to retail pharmacy; that it will support and indemnify any retail pharmacy that is taken to court by Pfizer as part of the current patent infringement case that started shortly after Teva launched generic atorvastatin on 20 June.

A Teva spokesperson said: “We value the trust our pharmacy customers have placed in us with generic atorvastatin, and we’d like to thank each and every one of them for their loyalty.”

As the dispute around the interim injunction has been resolved following an agreement between the parties, there was no court hearing on 11th July. The case will now go straight to trial where the validity of the Pfizer’s patent will be debated. As a result, Teva confirms there is no change around the current status with the supply and dispensing of generic atorvastatin:

• Pharmacies are not prevented from dispensing generic atorvastatin they have already purchased.
• No retail pharmacy is the subject to an injunction.
• In the unlikely event that Pfizer takes any action against dispensing pharmacists, Teva stands by its promise to provide full legal assistance and support.
• Teva and the wholesalers cannot ship any further generic atorvastatin orders.

Teva’s spokesperson said: “We have said it before and we say it again – our view is that Pfizer’s patent protection in place for Lipitor® (atorvastatin) is invalid. We believe the validity of Pfizer’s patent is an issue that is appropriately determined in the courts between Teva and Pfizer and does not need to involve pharmacy.”

Teva expressed its disappointment with Pfizer’s continuing attempts to frighten individual pharmacies by threatening to drag them into the patent litigation case. The spokesperson added: “The choice whether to dispense generic atorvastatin is yours and yours alone to make. But, one question you must ask yourself is why Pfizer is attempting to act in this way and whether succumbing to this sort of bullying tactic is in the best interests of pharmacy in the long-term. We’d like to underline what Mr Justice Floyd said on 27 June, which was that ‘the actual dispensing of the product is not the basis of the harm to the claimants.’”

“We stand by our pharmacy customers, and reiterate the promise that we are willing to provide all legal costs and pay all damages for any pharmacy who is sued by Pfizer. We feel strongly that we are acting in the interests of sustainable healthcare delivered via the pharmacy.”

“We are looking forward to the trial. We intend to win and resume supply to our loyal customers as soon as possible; we will be taking our arguments to court and fighting our case.”

- ENDS -

Ref: GEN/11/032
11 July 2011

For media enquiries, contact the Teva UK Limited Communications team on 01977 628500, or email media.enquiries@tevauk.com.

Notes to Editors:

The latest order from 8th July 2011 can be viewed by clicking here.

The order from 27th June 2010 can be viewed by clicking here.

About Teva UK Limited
Teva UK Limited is one of the UK’s top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd.

About Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,450 molecules and a direct presence in 60 countries. Teva's branded businesses focus on neurological, respiratory and women's health therapeutic areas as well as biologics. Teva's leading innovative product, Copaxone®, is the number one prescribed treatment for multiple sclerosis. Teva employs approximately 40,000 people around the world and reached $16.1 billion in net sales in 2010.

Update on generic atorvastatin

2011-07-04 14:23:59

29 June 2011

Dear customer

Update on generic atorvastatin

You’ll be aware that we launched generic atorvastatin on 20th June, and you’ll also be aware that Pfizer was granted a temporary injunction on that date against us, AAH and Phoenix that prevents those three parties accepting any more orders at least until a full hearing scheduled for 11th July.

On Monday 27th June, a further hearing in the High Court was held to decide certain points of the case. You may be interested to read the following points from the hearing:

• Pfizer sought and failed to obtain an injunction against Rowlands Pharmacy. At this time this application was refused and therefore the situation remains that NO RETAIL PHARMACY is currently the subject of an injunction in this case.

• The judge expressly clarified that Teva were not prevented from offering an indemnity to dispensing pharmacies to cover them in the event of action being taken against them in relation to this case.

We feel strongly that we are acting in the interests of sustainable and affordable healthcare delivered via the pharmacy, and we will do our utmost to support our customers. In the unlikely event that any action is taken against any more dispensing pharmacists, Teva will provide full legal assistance and support.

If you have any questions, please call Teva’s direct helpline on 0800 085 8621.

We want to be your preferred generics manufacturer today and tomorrow, and we believe strongly that we always try to act in your best interests.

Yours faithfully

Teva UK Limited

GEN/11/028a
Date of preparation: June 2011

Teva transforms generics offering

2011-04-26 10:28:56

Teva UK Limited is transforming its offering to its independent pharmacy and dispensing doctor customers with the launch of a brand new generics buying scheme.

Teva, which was the first generics house to introduce a generics buying scheme back in 2003, says it has consulted its customers to find out exactly what they want from a generics scheme and has incorporated this into a brand new offering.

The company says that all customers have to do is to make a simple choice: TevaOne or TevaTwo. Whichever one best suits their business. This will depend on whether they would prefer base monthly rebates combined with a bonus quarterly rebate (TevaOne), or whether they can commit to a minimum spend of £2,500 per month to earn Nett Price and incremental levels of rebates (TevaTwo).

Said Kim Innes, Teva’s Commercial Director: “We’ve taken a long, hard look at our customer buying schemes. We asked our customers what they wanted, what they valued most from their generic medicines provider, and we listened. We’ve used their feedback to form the backbone of the change in our generic buying schemes – keeping them simple, reliable, and competitively priced.”

TevaOne and TevaTwo will launch on 1 May 2011, replacing the current offerings. Teva’s dedicated team of Account Managers is there to support the company’s customers every step of the way and will be in touch shortly to discuss which of the new schemes is right for them.

More information is also available online at www.tevauk.com/tevascheme. Any questions can be directed to the freephone helpline 0800 085 8621.

To find out more about Teva UK Limited, visit www.tevauk.com.

-ENDS-

For media enquiries, contact the Teva UK Limited Communications team on 01977 628500, or email media.enquiries@tevauk.com.

Teva Ref: SCH/11/001a

Teva UK scores exclusive launch of generic Lacidipine film-coated tablets

2011-03-28 16:47:14

We are pleased to announce the exclusive launch of a generic version of lacidipine film-coated tablets.

Lacidipine is a generic version of Motens® (lacidipine) from Boehringer Ingelheim Limited – a calcium-channel blocker, which is indicated in the treatment of hypertension, either alone or in combination with other antihypertensive agents.

Teva is the first company to bring a generic version of this product to the UK market. It is available immediately in the award-winning Teva 360 livery, which is designed to aid patient safety, as 2mg and 4mg film-coated tablets in packs of 28.

The Teva retail price for the product is £2.80 for the 2mg tablets, and £2.95 for the 4mg tablets.

Kim Innes, Commercial Director at Teva UK Limited said: “We are delighted to be bringing the first generic version of this product to the UK market, and at the same time further broaden our portfolio, which is the widest of any UK generics supplier.”

To find out more about Teva UK Limited, visit www.tevauk.com.

Ref: GEN/11/012
March 2011

Teva UK Limited supports the future of pharmacy

2011-02-16 12:49:33

One of the biggest pharmaceutical companies in the UK is throwing a cash lifeline to the pharmacists of tomorrow who are struggling against the rising tide of tuition fees and the harsh economic climate.

For the third year running, in a bid to support the future of pharmacy, Teva UK Limited is awarding cash bursaries to students who are aiming for a degree level qualification in pharmacy or similar, but who may be suffering hardship without additional financial support.

The company’s HR Director Lynda Wilebore said: “As the UK’s leading generic pharmaceuticals company, we’re totally committed to pharmacy in the UK. This means we’re not only interested in supporting the pharmacists of today, but also in ensuring the pharmacists of tomorrow get the best possible start.

“We hope our bursary scheme will make an important contribution to the lives of under-privileged students in the UK, particularly at a time when financial considerations are becoming a prime concern for individuals wishing to take a degree course.”

The students are:
- Tahir Ali Shabir, a 26-year old from Heald Green in Stockport who is in the first year of his degree course at Keele University
- Whitney Yeboah, an 18-year-old student from Canning Town in London, who is in the first year of her degree course at Aston University in Birmingham
- Ian Osborne, a 19-year old from Romford in London, who is in the second year of his degree course at Keele University
- Layequr Rahman, a 20-year old from Bradford, who is in the second year of his degree course at the University of Bradford.

Layequr said: “A lot of students coming from my background aren't very motivated and don't believe they can achieve things in life or reach their ambitions because they feel deprived, both economically and culturally. Thanks to Teva I’ve been able to achieve my ambition.”

The Student Bursary Scheme is open to any home UK student who is either already attending, or who has been offered a place on, any full-time UK-based undergraduate course approved by a school of pharmacy or similar.

For further information, including an information pack, how to apply next year and selection criteria, please visit the Teva UK Limited website at www.tevauk.com/careers/bursary.

To find out more about Teva UK Limited, visit www.tevauk.com.

-ENDS-
Ref: CPE/11/001
February 2011

For media enquiries, contact the Teva UK Limited Communications team on 01977 628500, or email media.enquiries@tevauk.com.

Notes to Editors:

About Teva UK Limited
Teva UK Limited is one of the UK’s top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd.

About Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world’s largest generic drug maker, with a global product portfolio of more than 1,250 molecules and a direct presence in 59 countries.

Teva’s branded businesses focus on neurological, respiratory and women’s health therapeutic areas as well as biologics. Teva’s leading innovative product, Copaxone®, is the number one prescribed treatment for multiple sclerosis. Teva employs over 40,000 people around the world and reached $13.9 billion in net sales in 2009.

Teva launches Pramipexole tablets

2011-01-24 14:59:34

We are pleased to announce the launch of a generic version of pramipexole tablets in a range of strengths and pack sizes.

Pramipexole tablets are a generic version of Mirapexin® (pramipexole) from Boehringer Ingelheim and are available immediately in the award-winning Teva 360 livery, which is designed to aid patient safety. The strengths and presentations are as follows:

Product Strength Pack Size Teva retail price
Pramipexole 0.088mg tablets 30 £5.73
Pramipexole 0.18mg tablets 30 £11.46
Pramipexole 0.18mg tablets 100 £38.20
Pramipexole 0.35mg tablets 30 £22.92
Pramipexole 0.35mg tablets 100 £76.40
Pramipexole 0.7mg tablets 30 £45.84
Pramipexole 0.7mg tablets 100 £152.81

Kim Innes, Commercial Director at Teva UK Limited said “We are delighted to be bringing a generic version of this product to the UK market, and at the same time further broaden our portfolio, which is the widest of any UK generics supplier.”

To find out more about Teva UK Limited, visit www.tevauk.com.

Gabapentin 300mg capsules recall

2010-12-22 16:39:16

DRUG ALERT CLASS 2 MEDICINES RECALL – action within 48 hours
Pharmacy and wholesaler level recall
Date of recall: 22 December 2010

Product: Gabapentin 300mg capsules
Product Licence No: 00289/0590-0592
PIP Code: 110-8174
Batch numbers: 003784, 003795, 003796 and 003798

Gabapentin Capsules 300mg in Teva UK livery Product Licence No: 00289/0590-0592
Batch Number Expiry Date Pack Size First Distributed
003784 June 2012 X 100 August 2010
003795 June 2012 X 100 August 2010
003796 June 2012 X 100 August 2010
003798 June 2012 X 100 August 2010

Further to the Drug Alert issued by the MHRA on 22nd December 2010 (Ref: MDR 42-12/10), Teva UK Limited is recalling all remaining stock of the above batches as a precautionary measure. Routine testing of retained samples has uncovered a small number of capsules with low fill weights.

Please note that no other batches are affected by this.

Remaining stocks of the recalled batches should be returned to the wholesaler from whom the stock was purchased. It is NOT necessary to ask patients to return product. Any queries should be directed to Teva UK Limited on 0800 590502 – medical information enquiries, please contact Teva UK Limited on 020 7540 7117. For out of hours calls, please call Teva UK Limited on 020 7540 7000.

Please help us serve the pharmacy community by including a reference to the above recall in the next issue of your magazine.

Ref: 098/COP/10b
Date: 22 December 2010

Teva launches Prednisolone EC tablets

2010-11-23 16:17:34

We are pleased to announce the launch of a generic version of Prednisolone enteric-coated (EC) tablets.

Prednisolone EC tablets are a generic version of Deltacortril® from Alliance Pharmaceuticals Limited and are indicated in the treatment of inflammatory and allergic conditions such as asthma, rheumatoid arthritis and colitis.

Prednisolone is available immediately in the award-winning Teva 360 livery, which is designed to aid patient safety, as 2.5mg and 5mg enteric-coated tablets in pots of 28 tablets.

The Teva retail price for the product is £8.57 and £8.65 for the 2.5mg and 5mg tablet packs respectively.

Kim Innes, Commercial Director at Teva UK Limited said “We are delighted to be bringing a generic version of this product to the UK market, and at the same time further broaden our portfolio, which is the widest of any UK generics supplier.”

To find out more about Teva UK Limited, visit www.tevauk.com.

-ENDS-

Ref:

Ref: TEVAG10/ED/10
Date: November 2010

Notes to Editors:
For media enquiries, contact the Teva UK Limited Communications team on 01977 628500, or email media.enquiries@tevauk.com.

About Teva UK Limited
Teva UK Limited is one of the UK’s top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd.

About Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world’s largest generic drug maker, with a global product portfolio of more than 1,250 molecules and a direct presence in 59 countries.

Teva’s branded businesses focus on neurological, respiratory and women’s health therapeutic areas as well as biologics. Teva’s leading innovative product, Copaxone®, is the number one prescribed treatment for multiple sclerosis. Teva employs over 40,000 people around the world and reached $13.9 billion in net sales in 2009.

Teva UK Limited enters wounds sector with PolyHeal™ launch

2010-11-15 10:22:53

Teva UK Limited, a leading supplier of medicines to the NHS, has today entered the Wound Care sector with the launch of PolyHeal at the Wounds UK conference. PolyHeal is a product for hard-to-heal wounds and has been clinically shown to result in a significant reduction in wound size after just one month’s treatment – even in wounds with exposed bones and tendons.

The product consists of negatively charged polystyrene microspheres, suspended in a nutrient medium, which interact with cellular components within the wound bed to activate the inflammatory and proliferation phases of wound healing1,2. It has clinically proven results in treating hard-to-heal wounds across a variety of wound types3:
- Granulation coverage in 63% of wounds after four weeks
- 40% wound size reduction after four weeks
- 36% of wounds closed within 12 weeks

The results of two open-label studies of chronic wounds of multiple aetiologies – including venous, diabetic and ischaemic ulcers – showed that 87% of patients treated with PolyHeal achieved significant wound improvement after four weeks of treatment3. Furthermore, all exposed bones and tendons were covered after four weeks3.

Speaking at the launch, Robyn Hughes, Primary & Secondary Care Director at Teva, said: “We’re delighted to bring this exciting new product to the UK market and believe it will make a real difference to patients suffering from hard-to-heal wounds.” Marketing Manager, Dr Andrew Ellis, added: “There remains an unmet need in the treatment of chronic wounds – we are confident that PolyHeal will become a cornerstone of therapy in this challenging market segment.”

The product will be available from wholesalers in January 2011.

To find out more about Teva UK Limited, visit www.tevauk.com

-ENDS-
For media enquiries, contact the Teva UK Limited Communications team on 01977 628500, or email media.enquiries@tevauk.com.

Notes to Editors:
References:
1) Dulbecco’s Modified Eagle’s Medium (DMEM)
2) PolyHeal™ Instructions For Use
3) Zeilig G. et al. Study to evaluate PolyHeal-1 in treatment of recalcitrant wounds. DOF November 2010

Ref: CPE/10/025

Teva UK Limited comments on Department of Health generic substitution outcome

2010-10-14 16:11:16

Teva UK Limited, the UK’s leading manufacturer of generic medicines, has today commented on the Department of Health’s (DH) decision not to implement generic substitution in primary care.

Although deciding not to go ahead with generic substitution as the original proposals stood, DH has indicated that it will be “looking at further ways to support the use of generic medicines in a way that is acceptable to patients, recognising that there are still some savings that can potentially be delivered in this area”.1

Says Richard Daniell, Commercial Operations Officer at Teva: “Teva is fully supportive of DH’s aim to increase access to affordable medicines by encouraging cost-effective generic prescribing as an equivalent alternative to branded prescribing where there is no clinical reason not to do so.”

Generic medicines maintain the same standards of quality, safety and efficacy as the originator brand at an average of 20% of the cost, and deliver £8.6 billion of savings to the NHS each year.2

Adds Richard: “To continue to prescribe by brand where there is an equivalent clinically-proven and cost-effective alternative prevents NHS funds being used in other ways. As the UK’s leading manufacturer of generic medicines, Teva would welcome the opportunity to work with DH to help maximise generic contribution to the NHS and save the UK tax payer even more.”

To find out more about Teva, visit www.tevauk.com.

-ENDS-

For media enquiries, contact the Teva UK Limited Communications team on 01977 628500, or email media.enquiries@tevauk.com.

References:
1 DH website http://www.dh.gov.uk/en/Consultations/Responsestoconsultations/DH_120431 – 14/10/10
2 BGMA Press Release 14/10/2010

Ref: CPE/10/021
14 October 2010

About Teva UK Limited
Teva UK Limited is one of the UK’s top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd.

About Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world’s largest generic drug maker, with a global product portfolio of more than 1,250 molecules and a direct presence in 59 countries.

Teva’s branded businesses focus on neurological, respiratory and women’s health therapeutic areas as well as biologics. Teva’s leading innovative product, Copaxone®, is the number one prescribed treatment for multiple sclerosis. Teva employs over 40,000 people around the world and reached $13.9 billion in net sales in 2009.

Teva voted “great place to work”

2010-10-12 09:45:21

Teva UK Limited has been voted a “great place to work” by its employees. Some 82% of all staff who completed a recent employee satisfaction survey are classed as “engaged” with the company, or positively disposed towards Teva and its values.

Not only is this better than the national average (72%), but it is also higher than the Best UK Employer (81%). Other results showed that 88% of employees feel proud to tell people they work for the company, and 90% felt they could successfully manage the pressures of their work.

Earlier this year, Teva was awarded a One Star Status under the Best Companies Accreditation 2010. This was a big achievement for the company in its first attempt in these awards – and the latest employee satisfaction survey is serving to cement its reputation as a great place to work.

Lynda Wilebore, the company’s HR Director, said: “We’re delighted with these results. We value the feedback from our employees, and it’s great that so many of them have had so many positive things to say. We’ll continue to benchmark the company both internally and against other UK leading employers, to maintain continuous improvement and ensure that Teva remains a great place to work.”

To find out more about working at Teva, visit the company’s new careers website at www.tevaukcareers.com, or its main corporate website at www.tevauk.com.

-ENDS-

Notes to Editors:
To find out more about Teva UK Limited, visit www.tevauk.com. For media enquiries, contact the Teva UK Limited Communications team on 01977 628500, or email media.enquiries@tevauk.com.

About Teva UK Limited
Teva UK Limited is one of the UK’s top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd.

About Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world’s largest generic drug maker, with a global product portfolio of more than 1,250 molecules and a direct presence in 59 countries.

Teva’s branded businesses focus on neurological, respiratory and women’s health therapeutic areas as well as biologics. Teva’s leading innovative product, Copaxone®, is the number one prescribed treatment for multiple sclerosis. Teva employs over 40,000 people around the world and reached $13.9 billion in net sales in 2009.

Teva UK Limited launches Dorzolamide/Timolol Ophthalmic Solution

2010-10-01 11:40:49

We are pleased to announce the launch of Dorzolamide/Timolol 20mg/5mg per ml ophthalmic solution.

It is indicated in the treatment of elevated intra-ocular pressure (IOP) in patients with open-angle glaucoma or pseudo-exfoliative glaucoma when topical beta-blocker monotherapy is not sufficient1.

It is a generic version of Cosopt® from Merck Sharp & Dohme Limited and is available immediately in the award-winning Teva 360 livery, which is designed to aid patient safety, as Dorzolamide/Timolol 20mg/5mg per ml Ophthalmic Solution 5ml in a single pack.

The Teva retail price for the product is £9.05.

Kim Innes, Commercial Director at Teva UK Limited said “We are pleased to add this product to our ever-expanding product portfolio – the widest of any UK generics supplier.”

To find out more about Teva UK Limited, visit www.tevauk.com.

Ref: GEN/10/018

Teva welcomes The Bow Group report on pharmacy

2010-09-30 11:46:56

Teva UK Limited welcomes the findings of The Bow Group Health and Policy Committee that the better use of pharmacists could save millions of pounds from the NHS budget1.

The Committee’s research suggests that Enhanced Pharmacy Services are an under-utilised resource that can deliver innovative, cost-effective services to patients in a highly accessible manner.

The report concludes that over £812 million could potentially be saved if all patients with minor ailments were to receive pharmacy consultations. It notes that an average pharmacy consultation is £14.25 less expensive than an average GP consultation (£17.75 versus £32).

It also suggests that any excess profits earned above the threshold agreed in the Community Pharmacy Contract should be retained within pharmacy through the stablishment of an “Enhanced Pharmacy Service innovation fund”, which should serve to enable evidenced based commissioning of Enhanced Services to improve local health outcomes.

Kim Innes, Commercial Director at Teva UK Limited, says: “We know that running a pharmacy is becoming increasingly challenging, and welcome the publication of this report which has some innovative suggestions for maximising the use of pharmacy services in the UK. We’ll continue to support harmacy in the UK and assist them as best we can in making the best of their role in community healthcare.”

Ref: CPE/10/015

Teva UK Limited launches new careers website

2010-09-21 14:54:17

It’s now even easier to apply for a career with Teva UK Limited, after the UK’s leading generics manufacturer launched a brand new recruitment website.

Found at www.tevaukcareers.com, the website not only showcases the company’s latest vacancies, it also tells potential candidates exactly what it is like to work for Teva. One of the biggest pharmaceutical companies in the UK, Teva specialises in medicines whose patents have expired, and respiratory medicines, especially inhalers to relieve the symptoms of asthma.

The website features testimonials from a range of current employees. There’s also information about the company, its mission, vision and values, and details about the company culture – giving applicants a real flavour of what it is like to be a Teva employee.

Lynda Wilebore, the company’s UK HR Director, said: “Launching this website is part of showing that Teva is a great place to work – and makes it as easy as possible for job hunters to find the ideal role with Teva. We recently achieved a One Star Status under the Best Companies Accreditation 2010, with high ratings in the My Team, My Company and My Manager categories. This website builds on this success, helping potential candidates start their relationship with the company even before starting work here.”

Potential candidates can register their details, upload their CV and receive RSS alerts* letting them know of the latest vacancies. The roles will be at one of the company’s four UK sites – the head office in Castleford, West Yorkshire; Eastbourne, East Sussex, which is a Centre of Excellence for Packaging within Teva; the Centre of Excellence for Regulatory Affairs in Harlow, Essex; and the City office in Fleet Street, London, where the Legal team is based. A wide variety of roles will be advertised, from Quality and Regulatory, to Packaging and Distribution, Finance, Legal, IT and Marketing. There will also be field-based sales roles.

For more information, visit www.tevaukcareers.com.

- ends -

*RSS alerts: RSS, or really simple syndication, allows you to see when sites from all over the internet have added new content. You can get the latest headlines and articles (or even audio files, photographs or video) in one place, as soon as they are published, without having to remember to visit each site every day.

To use RSS, you need a news reader – a piece of software that checks RSS feeds and lets you read any new articles that have been added to them. Then, decide what content you want to receive in your news reader, by finding and subscribing to the relevant RSS feeds. For example, if you would like the latest Teva careers updates, simply visit www.tevaukcareers.com/xmlFeeds/LiveVacancies.aspx

About Teva UK Limited: Teva UK Limited is one of the UK’s top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) which has 38,000 employees based in 70 countries around the world.

Date of preparation: September 2010
Our ref: CPE/10/012

Teva donates medicines to Pakistan flood victims

2010-09-21 14:50:00

Teva UK Limited, the UK’s leading generics supplier, has made a major donation to the relief effort in Pakistan.

The company has given almost 35,000 doses of medicines – mainly life-saving antibiotics – to its nominated charity, International Health Partners (IHP) to distribute in the area.

Richard Daniell, Teva’s Commercial Operations Officer, said: “We’re pleased to be able to make this donation, which we sincerely hope will help some of the victims of this disaster in Pakistan. As a company, we aim to help make quality healthcare accessible around the world, and are pleased to be able to work with IHP once again to be able to do this for the victims of this tragedy.”

Teva has been donating medicines in partnership with IHP since last year, and also provides the charity with facilities at its Eastbourne site to make up doctor packs, which are used in countries such as Tanzania and India.

To find out more about Teva, visit www.tevauk.com. For more on IHP, visit www.ihpuk.org.

- ends -

About Teva UK Limited: Teva UK Limited is one of the UK’s top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) which has 38,000 employees based in 70 countries around the world.

For media enquiries, telephone the Teva Communications team on 01977 628500, or email media.enquiries@tevauk.com.

Ref: 088/COP/10
Date: September 2010

Teva UK Limited repeats Student Bursary offer

2010-09-21 14:31:25

Teva UK Limited, the UK’s leading generics manufacturer, has opened up its Student Bursary Scheme for the third year running.

The company launched the bursary scheme in 2008 as part of plans to extend its support of pharmacy in the UK. Student bursaries are available to students who want to gain a degree-level qualification in pharmacy or similar but may suffer hardship without additional financial support. Last year, bursaries were awarded to five individuals currently studying for a pharmacy degree at university, who each receive a payment of £500 for up to three years of study, providing they continue their studies.

Teva is running the scheme again in 2010, and says that it is now more important than ever to offer this kind of help. Lynda Wilebore, the company’s UK HR Director, said: “We hope this scheme will make an important contribution to lives of under-privileged students in the UK, particularly at a time when financial
considerations are becoming a prime concern for individuals wishing to undertake a degree course.”

She added: “As the UK’s leading generics company, we’re completely committed to pharmacy in the UK.
This means we’re not only interested in supporting the pharmacists of today, but also in ensuring the
pharmacists of tomorrow get the best possible start. We believe it is important to have a community support
programme that is relevant to our business.”

The Student Bursary Scheme is open to any UK home student who is either already attending, or who has
been offered a place on, any full-time UK-based undergraduate course approved by a school of pharmacy or similar. Each year, bursaries comprising of £500 payment for each year of study will be offered to students who may suffer difficulty without additional financial support. Applicants should be in receipt of the Education Maintenance Allowance or Carers Allowance. The closing date for the next round of applications is 15th October 2010.

For further information, including an information pack, how to apply and selection criteria, please visit www.tevauk.com

- ends -

About Teva UK Limited: Teva UK Limited is one of the UK’s top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) which has 38,000 employees based in 70 countries around the world.

For media enquiries, telephone the Teva Communications team on 01977 628500, or email media.enquiries@tevauk.com.

CPE/10/009

Teva UK Limited delivers “Good health for less.”

2010-09-07 11:11:51

Teva UK Limited, the UK’s leading generics manufacturer, is entering a whole new market sector by launching an over the counter (OTC) range of medicines.

Delivering “Good Health for less”, the comprehensive range will initially feature high quality analgesic, gastro-intestinal, allergy and cold and flu relief products, with more than 20 lines in total (P1 and GSL2).

Ryan Ruscoe, OTC Brand Manager for Teva UK Limited, says: “We’ve selected the range to meet consumers’ everyday healthcare needs, and to give them a real alternative to leading brand remedies.”

He adds: “This is a great opportunity for pharmacy to deliver superb value to their customer and achieve excellent returns on their bottom line through a quality range of good value products. We’re delighted that Teva – the established name behind the counter – will soon be available over the counter.”

Kim Innes, Teva’s Commercial Director, explains: “We’re always looking at different ways to help our pharmacy customers. Our generics portfolio is already the widest of any other UK generics supplier, and branching out into OTCs seems like the next logical step. We believe that our OTC range will really add further value, helping them achieve their business goals in this challenging healthcare environment.”

A full consumer launch is scheduled for the autumn, and further products will also be launched in the new year.

The range is now available to pre-order, and pharmacists can get in touch with their usual sales Teva contact, on 0800 085 8621 or via www.tevauk.com/consumerhealth to register their interest.

Press notice of DRUG ALERT – Class 3 medicines recall (pharmacy level)

2010-07-12 17:33:42

Press notice of DRUG ALERT – Class 3 medicines recall (pharmacy level)
Date of recall: 12 July 2010 − action within 5 days

Glibenclamide 5mg Tablets in Teva UK Limited and Generics (UK) Limited Livery
Product Licence No 00289/0048, PIP codes 1081066 and 1094424

Batch number Expiry date Pack size First distributed

Teva UK Limited livery, PIP code 1081066
000537 September 2012 1x28 18 Nov 2009
001315 September 2012 1x28 11 Mar 2010

Generics (UK) Limited livery, PIP code 1094424
000681 September 2012 1x28 23 Nov 2009

Further to the Drug Alert issued by the MHRA on 15th March 2010 (EL (10) A/06 Rev1), Teva UK Limited is recalling all remaining stock of the above batches as a precautionary measure. Routine stability testing has indicated that the specification for tablet dissolution may not be met after 12 months from manufacture. All batches which may be non-compliant were manufactured using a single batch of active ingredient.

We now have new stock of this product in order to avoid market shortages. Remaining stocks of the recalled batches should be returned to the wholesaler from whom the stock was purchased. It is NOT necessary to ask patients to return product. Any queries should be directed to Teva UK Limited on 0800 590502.

Please help us serve the pharmacy community by including a reference to the above recall in the next issue of your magazine.

Julie Booth
Communications Manager
01977 628640
07785 341328
email: julie.booth@tevauk.com

Date of preparation: July 2010
Ref: 80b/COP/10

Pharmaceutical company gets creative in the community

2010-06-08 16:27:41

Pharmaceutical company gets creative in the community Pharmaceutical company Teva UK Limited, based on Whistler Drive, Castleford, has joined forces with local community group the Castleford Heritage Trust. The most recent activity involved Teva and local mosaic artist Julie Hand, who worked with the local community to create some fantastic mosaic artwork for Teva’s impressive head office and logistics centre. Teva has now been in the area for over a year, and has been supporting Julie through the Bridge Arts centre at Sagar Street in Castleford over this period, running five mosaic workshops involving two local schools and two adult classes. Julie’s last workshop to produce a piece of mosaic artwork was for both members of the local community and Teva employees. The piece will be displayed in the reception area of Teva’s Whistler Drive facility. Commented Anna Grant, Teva’s Community Relations Officer, “We’re delighted to be able to offer our support to local community activities like those organised by the Castleford Heritage Trust. It makes us really proud to know that the local community and some of our own employees have created this fantastic individual piece of mosaic artwork for our reception area.” Artist Julie Hand said, “Working with Teva on all of the workshops has been very rewarding, having seen the enthusiasm and enjoyment of all those who participated. The mosaic I designed for Teva was inspired by their ethos of health and well-being, and so I hope that all who view it enjoy it, and think of those who worked with me to create it”. Alison Drake, Chair of the Castleford Heritage Trust said, “Teva has been committed to being involved with the local community before they even moved to the area. They’ve helped us make sure our heritage is kept alive by showing a great interest in the Trust and how we work with the local area and the great range of activities we offer.” To find out more about Teva, visit www.tevauk.com. Picture attached L – R - Julie Hand, Kim Innes, Commercial Director, Teva UK Limited. - ends - About Teva UK Limited: Teva UK Limited is one of the UK’s top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) which has 38,000 employees based in 70 countries around the world. For media enquiries, telephone the Teva Communications team on 01977 628500, or email media.enquiries@tevauk.com.

Teva welcomes All-Party Pharmacy Group policy action plan ahead of election

2010-04-27 12:59:21

Leading generic medicines manufacturer Teva UK Limited has welcomed the publication of the All-Party Pharmacy Group’s (APPG) policy action plan.(1 )

The APPG’s plan, entitled “100 days to make a difference”, seeks to influence the incoming Government to expand the role of pharmacy to drive quality and deliver greater efficiency in the NHS in the years ahead. The actions focus on areas which the APPG feels the Government must prioritise in its first 100 days of power.

Richard Daniell, Commercial Operations Officer at Teva, commented: “We welcome the APPG’s action plan, as its’ recommendations are patient-focused, and also recognise the important role of pharmacy in the front-line of primary care provision.”

Teva supplies more packs of medicine to the NHS each year than anyone else(2), and is the leading manufacturer of generic medicines – products where the patent has expired – in the UK(3). The UK generics industry saves the NHS £8.6 billion each year(4).

To find out more about Teva, visit www.tevauk.com

- ends -

Notes to editors

References:

1 APPG Policy Action Plan document.
2 IMS BPI/HPAI audit September 2009 and BGMA audit September 2009.
3 IMS BGMA audit - September 2009.
4 BGMA Press Release 05/01/2010

About Teva UK Limited: Teva UK Limited is one of the UK’s top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) which has 35,000 employees based more than 60 countries around the world.

For media enquiries, telephone the Teva Communications team on 01977 628500, or email media.enquiries@tevauk.com.

72/COP/2010 – Date of preparation: April 2010

Teva UK Limited welcomes DH consultation on COPD strategy

2010-04-19 10:26:44

Teva UK Limited has welcomed the Department of Health’s (DH) consultation on a Strategy for Services for Chronic Obstructive Pulmonary Disease (COPD).

As well as outlining a strategy for COPD services, the document also incorporates a strategy for asthma management.

Says Robyn Hughes, Director for Primary & Secondary Care at Teva: “Teva wholeheartedly supports the DH proposed strategy for COPD. The strategy seeks to put patient health at the centre by enabling patients to manage their condition themselves, and we believe this is key to its successful implementation.”

Adds Robyn: “We know it’s important that patients understand the importance of lung health and risk factors, and these proposals seek to address the current situation where we have an estimated 2 million undiagnosed UK patients with COPD.”1

The report also highlights issues around patients with asthma, and the importance of patient inhaler technique and of taking preventer medicine on a daily basis.1

The aim of the DH strategy is to ensure that COPD and asthma services are effective, give the patient control of their condition, and provide good value for money for taxpayers. The consultation runs until the end of April 2010.

Teva’s sales of respiratory products such as inhalers make it the second largest pharmaceutical company in the UK market by number of respiratory products sold.

To find out more about Teva, visit www.tevauk.com.

- ends -

Reference:
1. http://www.dh.gov.uk/en/Consultations/Liveconsultations/DH_112977 1/4/2010

Notes to editors:
Teva UK Limited is one of the UK’s leading pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. Measured by the volume of boxes supplied, it is the biggest single medicines supplier to the NHS. With over 500 product lines, it has the widest range of any UK generic pharmaceutical company and has a number of respiratory products including the Qvar® (beclometasone dipropionate) CFC-free inhaler.

For media enquiries, telephone the Teva Communications team on 01977 628500, or email media.enquiries@tevauk.com.

Teva UK Limited launches temozolomide capsules

2010-03-31 17:44:42

We are pleased to announce the launch of temozolomide available in 5mg, 20mg, 100mg, 140mg, 180mg and 250mg strength capsules. Temozolomide is indicated for the oncological treatment of brain tumours, specifically1:

• adult patients with newly-diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment.
• children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.

It is a generic version of Temodal® from Schering-Plough and is available immediately in the award-winning Teva 360 livery, which is designed to aid patient safety.

Robyn Hughes, Director of Primary and Secondary Care at Teva UK Limited said “We are proud to be the first to bring temozolomide to the generic market, and we view this product as an important addition to our oncology portfolio.”

References
1. Temozolomide - Summary of Product Characteristics

- ends -

About Teva UK Limited: Teva UK Limited is one of the UK’s top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) which has 38,000 employees based in 70 countries around the world.

MEP finds pharma facts

2010-03-11 11:35:19

Linda McAvan, MEP for Yorkshire and Humberside, toured the Teva UK Limited head office and distribution centre today (Friday 5 March). The visit was prompted by her role as Rapporteur for the European Parliament on proposals to strengthen the EU’s regulatory framework on pharmacovigilance1, meaning that she is the lead EU Parliamentarian steering new EU regulations on pharmacovigilance2.

Mrs McAvan toured the Teva distribution centre as well as meeting staff and had a briefing from Teva on issues affecting the generics industry. Mrs McAvan said: “Pharmacovigilance is crucial to ensuring that patients can be sure that their medication is safe; that systems are in place to prevent and report adverse drug reactions; and that manufacturers use their expertise and resources to put patient safety first. My visit to Teva, as the world’s biggest generic medicines manufacturer and a company with its UK base in my own constituency, gave me an insight into the valuable work that the industry is already doing to put patient safety at the centre of its thinking”.

Teva UK Limited CEO Dipankar Bhattacharjee said: “We were delighted to show Mrs McAvan the systems and processes we use to put patient safety first. We were also pleased to brief her on the wider issues facing the generic pharmaceutical industry and pharmacy across Europe. Pharmacy and the generics industry work together to make effective healthcare accessible and affordable, and we are keen to show governments and the European Union that more can still be done to put the patient at the centre of healthcare.”

1 Pharmacovigilance is defined as the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicine-related problems.

2 - http://www.europarl.europa.eu/oeil/FindByProcnum.do?lang=en&procnum=COD/2008/0257 last viewed 25 February 2010
- ends -

About Teva UK Limited: Teva UK Limited is one of the UK’s top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) which has 38,000 employees based in 70 countries around the world.

For media enquiries, telephone the Teva Communications team on 01977 628500, or email media.enquiries@tevauk.com.

MEP visits medicines masterpiece

2010-03-11 11:34:01

Linda McAvan, Labour MEP for Yorkshire and Humberside, went on a fact-finding tour today (Friday 5 March) to view one of the hidden wonders of Castleford – a huge state-of-the-art medicines distribution centre that supplies prescription medicines for millions of patients all over the UK. A huge building on the outskirts of the town, 200 metres long by 100 metres wide, sends life-saving medicines to pharmacies from Penzance to Peterhead; and Mrs McAvan is leading a drive in the European Parliament to improve rules on drug safety and reporting unusual reactions to taking a medicine – showing warning signs that could be used to protect others.

Summit Park-based Teva UK Limited is one of the biggest medicines manufacturers in the UK, making billions of tablets each year for just about every illness from headache to cancer. Mrs McAvan toured a robot-controlled distribution centre as well as meeting workers, and she had a briefing from Teva bosses on keeping patients as safe as possible when taking their medicines. Mrs McAvan said: “Millions of patients in Yorkshire, the UK and across Europe depend on the medicines they take. The European Parliament has asked me to lead an initiative to look at how we make sure that every pack of medicine on the pharmacy shelf is as safe as possible for patients. My visit to Teva has shown how politicians, medicines makers and pharmacists can work together to put the patient first.”

Mrs McAvan was shown around the Teva site by the company’s UK boss Dipankar Bhattacharjee. He said: “We were delighted to show Linda how we send our products safely on their way to medicine cabinets all over the UK, and of course to show her that a global company like Teva is investing to bring skilled jobs to Yorkshire. Our priority here is to make effective medicines that the NHS can afford, and we hope that Linda found the visit useful in her work to make sure that patients can trust the medicines they take to make them feel better.”

- ends -

About Teva UK Limited: Teva UK Limited is one of the UK’s top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) which has 38,000 employees based in 70 countries around the world.

For media enquiries, telephone the Teva Communications team on 01977 628500, or email media.enquiries@tevauk.com.

Teva UK Limited supports the future of pharmacy

2010-03-11 11:32:55

One of the biggest pharmaceutical companies in the UK is throwing a cash lifeline to the pharmacists of tomorrow who are struggling in today’s economic climate.

For the second year running, in a bid to support the future of pharmacy, Teva UK Limited is awarding cash bursaries to students who are aiming for a degree level qualification in pharmacy or similar, but who may be suffering hardship without additional financial support.

The company’s HR Director Lynda Wilebore said: “As the UK’s leading generics pharmaceuticals company, we’re totally committed to pharmacy in the UK. This means we’re not only interested in supporting the pharmacists of today, but also in ensuring the pharmacists of tomorrow get the best possible start.

“We hope our bursary scheme will make an important contribution to the lives of under-privileged students in the UK, particularly at a time when financial considerations are becoming a prime concern for individuals wishing to take a degree course.”

One of those students getting the best possible start is Hameed Anwar. His cash lifeline from Teva UK Limited is allowing him to pursue a dream job that could ultimately help his mother recover from a disabling condition.

The 20-year-old from Heaton in Bradford, wants to work in pharmacy, but he’s been struggling to muster the funds for the four-year Master of Pharmacy degree because his mum Sofia is battling Multiple Sclerosis at home.

Now Teva UK Limited has come to his rescue, giving Hameed £500 to help with each year of his study.

Hameed, who has just started the second year of his degree course at the University of Bradford, said: “I struggled financially with the first year of studies and was considering dropping out, but thanks to the Teva bursary, I can continue to fund my studies.

“Once I graduate I’d love to open my own pharmacy and who knows, by that time there could be advancements in the drug industry that I know about that could help my mum recover.”

Laura Scott, a 19-year-old student from Malton in North Yorkshire, also received a bursary from Teva. From the University of Bath, where she has just started her first year, she said: “The bursary is an absolute godsend because without the money, I wouldn’t be able to afford books and other necessities for university.

“My ambition is to work in the pharmacy industry, or maybe even run my own pharmacy shop. I’ve worked at the local pharmacy in my village and I really enjoyed that experience of helping people.”

A bursary also went to Matt Shepherd, a 19-year-old student from Middleton, near Manchester, who has just started the first year of his degree course at the University of Nottingham. He said: “I’m absolutely delighted with the financial help. It has relieved so much pressure on me and my parents, who were taking on extra jobs to try and pay for my studies.

“I’d love to work in a hospital environment or the pharmacy industry, designing new drugs to help people. Now, thanks to Teva, I can concentrate on my studies without having to worry so much about going into debt.”

Another delighted student is 18-year-old Elham Isa from Balham in London. Now in her first year at the University of Portsmouth, she said: “I’m delighted to get the bursary because I come from a low income family, so would have struggled financially to study at university.

“My dream is to work in a hospital pharmacy and then perhaps join a pharmaceutical company to carry out research into drugs and their effects. Hopefully now I can achieve my ambition.”

The Student Bursary Scheme is open to any home UK student who is either already attending, or who has been offered a place on, any full-time UK-based undergraduate course approved by a school of pharmacy or similar. Applicants should be in receipt of the Education Maintenance Allowance or Carer’s Allowance.

For further information, including an information pack, how to apply next year and selection criteria, please go to Teva UK Limited’s website at www.tevauk.com/careers

- ends -

About Teva UK Limited: Teva UK Limited is one of the UK’s top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) which has 38,000 employees based in 70 countries around the world.

For media enquiries, telephone the Teva Communications team on 01977 628500, or email media.enquiries@tevauk.com.

Teva UK Limited wins Best Companies Star Status

2010-03-11 11:27:44

Teva UK Limited has achieved a One Star Status under the Best Companies Accreditation 2010.

Winning the Star Status is a big achievement for Teva in the Company’s first attempt at these awards. The results highlighted that Teva scored particularly well in the My Team category, which is based around encouraging team spirit, feeling part of the company, having fun, and belonging. Teva also rated highly in the My Company and the My Manager categories.

Dipankar Bhattacharjee, Teva’s Chief Executive Officer, commented: “We’re delighted with our Star Status, especially with this being our first attempt at these prestigious awards. We value the feedback from our employees, so we’re particularly pleased to have been rated so highly by colleagues across a number of areas.”

Best Companies established the accreditation award scheme to acknowledge excellence in the workplace. Based on staff feedback, it looks at employee engagement as an integral part of a company’s success and growth, and sets a benchmark for other employers. The accreditation scheme follows a Michelin star style system with companies awarded one star for first class, two stars for outstanding and three stars for extraordinary performance.

Jonathan Austin, CEO and founder, Best Companies comments: “An engaged workforce is essential … only those that have kept on engaging their staff and making sure they are involved in the business will be in a good position for the future … the companies that have achieved accreditation are among the best employers, and are to be congratulated.”

Teva will continue to benchmark itself both internally and against other UK leading employers, to maintain continuous improvement and ensure that Teva remains a great place to work.

To find out more about Teva, visit www.tevauk.com.

- ends -

About Teva UK Limited: Teva UK Limited is one of the UK’s top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) which has 38,000 employees based in 70 countries around the world.

For media enquiries, telephone the Teva Communications team on 01977 628500, or email media.enquiries@tevauk.com.